COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vitamin D and Chronic Obstructive Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01416701
Recruitment Status : Withdrawn (It was not possible to enroll the planned amount of subjects. Many patients with chronic obstructive pulmonary disease already took large doses of vitamin D.)
First Posted : August 15, 2011
Last Update Posted : April 9, 2013
Information provided by (Responsible Party):
Jorgen Vestbo, Hvidovre University Hospital

Brief Summary:
The purpose of this study is to examine the effect of vitamin D intervention in patients with chronic obstructive pulmonary disease (COPD) undergoing rehabilitation.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Lung Disease Dietary Supplement: Vitamin D (D3, cholecalciferol) Dietary Supplement: Placebo (cellulose) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Vitamin D and COPD. A Randomised, Double-blind, Placebo-controlled Trial of the Effect of Vitamin D on Withdrawal From Pulmonary Rehabilitation and Exercise Endurance
Study Start Date : September 2011
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Vitamin D (D3, cholecalciferol) Dietary Supplement: Vitamin D (D3, cholecalciferol)
Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
Other Name: Bio Vinci Mega D-vitamin

Placebo Comparator: Placebo (cellulose) Dietary Supplement: Placebo (cellulose)
Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily

Primary Outcome Measures :
  1. Withdrawal from rehabilitation. [ Time Frame: 24 weeks ]
    Withdrawal will be defined as giving up rehabilitation or delaying any training visit by more than 3 weeks.

  2. Improvement in walking distance [ Time Frame: 24 weeks ]
    Change in walking distance from week 0 to week 24. Exercise capacity is evaluated using paced walking (Incremental Shuttle Walk Test(ISWT) and Endurance Shuttle Walk Test (ESWT)).

Secondary Outcome Measures :
  1. Change in vitamin D status. [ Time Frame: 52 weeks ]
    se-25-OHD se-PTH

  2. Change in calcium metabolic status. [ Time Frame: 52 weeks ]
    se-calcium se-phosphate se-magnesium

  3. Change in quality of life. [ Time Frame: 52 weeks ]
    COPD Assessment Test (CAT) and St George Respiratory Questionnaire (SGRQ).

  4. Change in status of bone metabolism. [ Time Frame: 52 weeks ]
    DXA (Dual energy X-ray Absorptiometry) scans

  5. Change in walking distance. [ Time Frame: 52 weeks ]
    Change in walking distance from week 0 to week 11 and week 52. Exercise capacity is evaluated using paced walking (Incremental Shuttle Walk Test (ISWT) and Endurance Shuttle Walk Test (ESWT)).

  6. Change in fat mass and fat free mass. [ Time Frame: 52 weeks ]
    Whole body DXA scans.

  7. Change in physical activity. [ Time Frame: 24 weeks ]
    Physical activity at home is measured over a week using an activity sensor (SenseWear Pro armband).

  8. COPD exacerbations. [ Time Frame: 52 weeks ]
  9. All cause hospital admissions. [ Time Frame: 52 weeks ]
  10. All cause mortality. [ Time Frame: 52 weeks. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 50 years
  • Diagnosed COPD with forced expiratory volume in 1 second (FEV1) < 50 % of predicted
  • Breathlessness relative to MRC dyspnoea grade 3 or more

Exclusion Criteria:

  • Patients with known diseases of bone metabolism apart from osteoporosis and patients with granulomatous disease
  • Patients with hyper- or hypocalcemia at inclusion
  • Patients with cardiovascular or musculoskeletal disease that impacts significantly on walking based on the investigator's judgement
  • Patients with dementia or other mental conditions rendering them unable to understand the study information and thus provide informed consent
  • Patients with terminal disease or known cancer with bone metastases, increasing their risk of hypercalcemia
  • Patients taking more than 20 mcg vitamin D on a daily basis. If a patient takes vitamin D below this limit, dose should have been stable 6 months prior to inclusion in order to achieve steady-state.
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01416701

Layout table for location information
Hvidovre University Hospital, Department of Respiratory Medicine
Hvidovre, Denmark, 2650
Medical Unit, Hvidovre University Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Jorgen Vestbo
Layout table for investigator information
Principal Investigator: Jørgen Vestbo, DMSc Hvidovre Universityl Hospital
Layout table for additonal information
Responsible Party: Jorgen Vestbo, Prof. DMSc, Hvidovre University Hospital Identifier: NCT01416701    
Other Study ID Numbers: DvitKOL01022011
First Posted: August 15, 2011    Key Record Dates
Last Update Posted: April 9, 2013
Last Verified: April 2013
Keywords provided by Jorgen Vestbo, Hvidovre University Hospital:
Vitamin D
Pulmonary rehabilitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents